Adeno‐associated virus‐mediated colonic secretory expression of HMGB1 A box attenuates experimental colitis in mice
Authors:
- 30 October 2016
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 18 (10) , 261-272
Abstract
Background: Extracellular high mobility group box 1 (HMGB1) is crucially implicated in the pathogenesis of inflammatory bowel diseases (IBDs). A box domain of HMGB1 has been identified as a specific antagonist of HMGB1. In the present study, we tested the effects of adeno‐associated virus (AAV)‐mediated colonic secretory expression of HMGB1 A box on murine experimental colitis.Methods: Self‐complementary AAV‐2 carrying mouse immunoglobin Gκ leader‐human HMGB1 A box (AAV‐HMGB1 A box) was constructed. The effects of intracolonically administered AAV‐HMGB1 A box on dextran sulfate sodium (DSS)‐ and 2,4,6‐trinitrobenzene sulfonic acid (TNBS)‐induced colitis were assessed by the disease activity index (DAI), colon length, macroscopic and histological scoring, myeloperoxidase (MPO) activity, and epithelial apoptosis and complementary proliferation. Colonic immune cell infiltrates, mucosal malondialdehyde content and superoxide dismutase activity, colonic tumor necrosis factor‐α (TNF‐α), interleukin (IL)‐1β and IL‐10 levels, serum HMGB1 concentration, and colonic HMGB1 release were determined to investigate the underlying mechanisms.Results: Intracolonically administered AAV‐HMGB1 A box efficiently mediated secretory expression of HMGB1 A box and led to significant decreases in DAI, macroscopic and histological scores and colonic epithelial apoptosis in both DSS‐ and TNBS‐treated mice. Modulating inflammation‐associated cytokines, such as inhibiting colonic TNF‐α and IL‐1β expression, decreasing HMGB1 release, and restoring colonic IL‐10 levels, and thereby inhibiting inflammatory cell infiltration and alleviating oxidant damage, might be the underlying mechanism.Conclusions: Intracolonic application of AAV‐HMGB1 A box is effective in alleviating murine colitis and has therapeutic potential in human IBDs.Keywords
This publication has 56 references indexed in Scilit:
- Dipotassium Glycyrrhizate Inhibits HMGB1-Dependent Inflammation and Ameliorates Colitis in MicePLOS ONE, 2013
- Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel diseaseProceedings of the National Academy of Sciences, 2013
- HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4Journal of Experimental Medicine, 2012
- The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand populationHuman Immunology, 2011
- Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitisJournal of Leukocyte Biology, 2009
- Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced ColitisInflammatory Bowel Diseases, 2009
- Defective IL-10 production in severe phenotypes of Crohn’s diseaseJournal of Leukocyte Biology, 2009
- Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLEJournal of Experimental Medicine, 2008
- A novel pathway of HMGB1‐mediated inflammatory cell recruitment that requires Mac‐1‐integrinThe EMBO Journal, 2007
- Localized colonic inflammation increases cytokine levels in distant small intestinal segments in the ratLife Sciences, 2006